For research and educational purposes only. Not medical advice.
Nafarelin Reference
Educational, not medical advice reference for Nafarelin: Reproductive, Hormonal; regulatory status, evidence posture, source review, and schedul…
Reference summary
Nafarelin is a label-verified intranasal GnRH agonist with multiple Phase 3 and post-marketing trials in endometriosis (Henzl 1988 NEJM and follow-on studies) showing pelvic-pain and lesion-size endpoints comparable to depot agonists, and a separate label evidence base in central precocious puberty showing pituitary downregulation with maintained adult-height outcomes. The hypoestrogenic state during continuous suppression drives a measurable bone-density loss that increases with cumulative treatment length, and the label caps endometriosis courses accordingly.
Regulatory and posture
- Categories
- Reproductive, Hormonal
- Aliases
- Synarel, Intranasal GnRH agonist, Nafarelin acetate, RS-94991
- Evidence posture
- human - Endocrinology drug. Prescription-only; off-label or self-administered use is unsafe. Bone-density loss accumulates with prolonged hypoestrogenic exposure, the label caps endometriosis courses, and add-back hormonal therapy is a common label-discussed mitigation.
- Regulatory status
- FDA-approved prescription medication (Synarel). Indications include endometriosis (in women) and central precocious puberty (in children). Prescription-only and patient self-administered as an intranasal spray after prescriber training.
- Content review status
- label verified